Andrew Pippas, MD
Medical Oncology · Columbus, GANPI 1831262922
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,425 of the $11,058 with a category attached, or 67.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 68.3% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $7,902 and has fallen 94.1% since, to $467 in 2025.
Across 159 payments — averaging $69.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Johnson & Johnson$544
- AbbVie$401
- Merck$288
- Gilead$274
- Seagen Inc.$156
- plus $2K from 35 others
Across 389 payments — averaging $4559.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$800K
- Astrazeneca UK Limited$213K
- AstraZeneca$140K
- AbbVie$127K
- Incyte Corporation$76K
- Beigene, Ltd.$70K
- plus $347K from 15 others
What the payments were for
- Speaking & faculty fees$7,42567%
- Food & beverage$2,46922%
- Education$1,16411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $7,547 |
| Johnson & Johnson | 19 | $544 |
| AbbVie | 9 | $401 |
| Merck | 18 | $288 |
| Gilead(2 entities) | 12 | $274 |
| Seagen Inc. | 4 | $156 |
| AstraZeneca(2 entities) | 10 | $155 |
| Mentor Worldwide LLC | 1 | $143 |
| Novartis | 6 | $137 |
| Daiichi Sankyo Inc. | 8 | $134 |
| Bristol Myers Squibb | 7 | $125 |
| Amgen | 8 | $113 |
| Array Biopharma Inc | 5 | $99 |
| Sobi, Inc | 1 | $99 |
| Exelixis Inc. | 1 | $85 |
| Pfizer | 6 | $82 |
| Terumo BCT, Inc. | 4 | $79 |
| Ipsen Biopharmaceuticals, Inc | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Eisai Inc. | 3 | $44 |
| Sirtex Medical Inc | 1 | $40 |
| Bayer | 2 | $31 |
| Incyte Corporation | 2 | $28 |
| Sanofi | 2 | $28 |
| Legend Biotech USA Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Novocure Inc. | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
| CTI Biopharma Corp. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,058 in reported general payments places this provider in the 60th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 77 | $1,365,954 |
| IbrancePalbociclib | 74 | $1,138,974 |
| TagrissoOsimertinib Mesylate | 62 | $988,788 |
| VerzenioAbemaciclib | 64 | $939,800 |
| Lenalidomide | 51 | $744,917 |
| ImbruvicaIbrutinib | 40 | $629,716 |
| XtandiEnzalutamide | 57 | $531,800 |
| CabometyxCabozantinib S-Malate | 21 | $514,899 |
| PomalystPomalidomide | 20 | $495,015 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $395,105 |
| AlunbrigBrigatinib | 12 | $225,260 |
| CalquenceAcalabrutinib Maleate | 13 | $187,624 |
| KisqaliRibociclib Succinate | 12 | $177,821 |
| TavalisseFostamatinib Disodium | 12 | $164,762 |
| InlytaAxitinib | 12 | $125,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $125 | $1,365,95477 claims |
| PfizerIbrance, Inlyta, Eliquis | $82 | $1,318,972162 claims |
| AstraZenecaTagrisso, Calquence | $155 | $1,176,41275 claims |
| Exelixis Inc.Cabometyx | $85 | $514,89921 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $54 | $495,01520 claims |
| GSKOjjaara | $19 | $395,10514 claims |
| NovartisKisqali, Gleevec | $137 | $241,56024 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $7,547 | $225,26012 claims |
| AbbVieVenclexta | $401 | $90,59215 claims |
| Johnson & JohnsonXarelto | $544 | $17,17939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Columbus
- Vetta HiggsColumbus$1K
- Wilbur BassettColumbus$637
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.